A5053997136- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Cervical Cancer and HPV Research
- Endometriosis Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Uterine Myomas and Treatments
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Renal cell carcinoma treatment
- Estrogen and related hormone effects
- Reproductive System and Pregnancy
- Cancer, Lipids, and Metabolism
- Lung Cancer Treatments and Mutations
- Chemotherapy-induced organ toxicity mitigation
- Gynecological conditions and treatments
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Advances in Oncology and Radiotherapy
- Cancer Risks and Factors
- Ultrasound and Hyperthermia Applications
- Cancer Research and Treatments
- Gastric Cancer Management and Outcomes
- Chromatin Remodeling and Cancer
Midorigaoka Hospital
2024
Mayo Clinic
2023
Jikei University School of Medicine
2011-2020
Charité - Universitätsmedizin Berlin
2016
Keio University
2004-2015
The Jikei University Hospital
2006-2013
Kagoshima City Hospital
2004-2010
Niigata Cancer Center Hospital
2010
Osaka City University
2010
University of Tsukuba
2003-2010
Abstract Purpose: We aimed to find key molecules associated with chemoresistance in ovarian cancer using gene expression profiling as a screening tool. Experimental Design: Using two newly established paclitaxel-resistant cell lines from an original paclitaxel-sensitive line and four supersensitive refractory surgical specimens paclitaxel-based chemotherapy, were screened arrays containing 39,000 genes. further analyzed 44 genes that showed significantly different expressions between samples...
Purpose The objective of this study was to assess clinical outcomes and fertility in patients treated conservatively for unilateral stage I invasive epithelial ovarian cancer (EOC). Patients Methods A multi-institutional retrospective investigation undertaken identify with EOC fertility-sparing surgery. Favorable histology defined as grade 1 or 2 adenocarcinoma, excluding clear cell histology. Results total 211 (stage IA, n = 126; IC, 85) were identified from 30 institutions. Median duration...
Purpose Farletuzumab is a humanized monoclonal antibody that binds to folate receptor-α, which highly expressed in ovarian carcinoma and largely absent from normal tissue. was investigated double-blind, randomized phase III study platinum-sensitive cancer. Patients Methods Eligible patients had first recurrent cancer 6-24 months following completion of platinum-taxane chemotherapy. All received carboplatin plus paclitaxel or docetaxel (for six cycles combined with randomly assigned test...
<h3>Introduction:</h3> Paclitaxel plus carboplatin (TC) is generally considered to be the "gold standard" regimen for treatment of epithelial ovarian carcinomas. Little data are available, however, on use this in patients with clear cell adenocarcinoma ovary (CCC). Combination chemotherapy irinotecan hydrochloride cisplatin has been reported effective primary and recurrent or resistant CCC. We compared these 2 combinations <h3>Methods:</h3> Patients (n = 99) CCC were randomly assigned...
Human epididymis protein 4 (HE4) levels and the Risk of Ovarian Malignancy Algorithm (ROMA) have recently been shown to improve sensitivity specificity epithelial ovarian cancer (EOC) diagnosis. We evaluated HE4 ROMA as diagnostic tools type I II EOC in Japanese women. Women who had a pelvic mass on imaging were scheduled undergo surgery enrolled patients. Serum carbohydrate antigen 125 (CA125) tested 319 women (131 benign, 19 borderline, 75 malignant, 94 healthy controls). CA125, HE4, for...
The purpose of this study was to develop a risk prediction score for distinguishing benign ovarian mass from malignant tumors using CA-125, human epididymis protein 4 (HE4), ultrasound findings, and menopausal status. compared the malignancy index algorithm (ROMA).This prospective, multicenter (n=6) with patients six Asian countries. Patients had pelvic upon imaging were scheduled undergo surgery. Serum CA-125 HE4 measured on preoperative samples, findings recorded. Regression analysis...
Cytokine expression in a tumor microenvironment can impact both host defense against the and cell survival. In this study, we sought to clarify whether cytokine gene profile could have clinical associations with ovarian cancer. We analyzed of 16 genes (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p35, IL-12p40, IL-15, IFN-γ, TNF-α, IL-6, HLA-DRA, HLA-DPA1 CSF1) 50 carcinomas. Hierarchical clustering analysis these tumors was carried out using Cluster software differentially expressed...
Abstract Allelic imbalance on chromosome arm 22q has been detected in 50–70% of ovarian cancers, suggesting the presence a tumor‐suppressor gene this that is involved carcinogenesis. Recently, we isolated candidate gene, MYO18B , at 22q12.1, which deleted, mutated and hypermethylated approximately 50% lung cancers. In our study, analyzed genetic epigenetic alterations Missense mutations were 1 4 (25%) cancer cell lines 17 (5.9%) primary expression was reduced all 12 (71%) restored by...
We previously reported that cyclin E (CCNE1) amplification is strongly associated with resistance to treatment in serous ovarian cancer by high-resolution oligonucleotide copy number analysis. Dysregulation of cell cycle control has been implicated as the key event human oncogenesis, and aberrant expression G1-S phase-related genes particular epithelial (EOC). Nevertheless, there are conflicting results concerning prognostic values these abnormalities EOC. This study focused on advanced EOC...
Adenomyosis patients treated with dienogest are considered to be at higher risk of uterine bleeding; however, the mechanisms which cause severe bleeding in those unknown. This study aims investigate factors among adenomyosis dienogest.Clinical data 51 were retrospectively collected from their medical records. The impact potential (age, sagittal square area uterus before treatment, and estradiol third month treatment) confounders (hemoglobin treatment prior treatments) on time discontinuation...